PCRX — Pacira BioSciences, Inc.

Summary of PCRX Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• EXPAREL Net Sales: Increased to $143.3 million, up from $136.5 million in Q1 2025, reflecting a volume growth of approximately 7%.
• ZILRETTA Sales: Rose 15% to $26.8 million compared to $23.3 million in the prior year.
• ioverao Sales: Increased 21% to $6.2 million from $5.1 million in Q1 2025.
• Non-GAAP Gross Margin: 80%, slightly down from 81% year-over-year.
• Adjusted EBITDA: Approximately $40.2 million for the quarter.
• R&D Expense: Increased to $25.4 million from $23.1 million in Q1 2025, driven by ongoing clinical studies.
• SG&A Expense: Reported at $83.9 million, up from $76.2 million, impacted by a favorable litigation outcome in the prior year.

2. Strategic Updates and Business Highlights

• Five by 30 Strategy: The company continues to execute its strategic plan aimed at enhancing patient access, revenue growth, profitability, pipeline development, and partnerships.
• EXPAREL Growth Drivers: Renewed growth attributed to expanded Medicare coverage, a new product-specific J-code, and increased awareness of non-opioid stewardship programs.
• ZILRETTA and ioverao: Both products are seeing growth due to dedicated sales forces and strategic partnerships, particularly with Johnson & Johnson MedTech.
• Pipeline Developments: Advancements in clinical-stage assets, including PCRX201 (gene therapy for knee OA) and PCRX2002 (hydrogel formulation of ropivacaine), with significant upcoming milestones.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Reiterated total revenues of $745 million to $770 million, with EXPAREL net sales projected at $600 million to $620 million.
• R&D and SG&A Forecast: Non-GAAP R&D expenses expected to be $105 million to $115 million; SG&A expenses projected at $320 million to $340 million.
• Adjusted EBITDA Expectations: Anticipated depreciation expense of approximately $30 million for 2026.

4. Bad News, Challenges, or Points of Concern

• Impact of Winter Storms: The first quarter was affected by winter storms, disrupting shipping and leading to procedure delays.
• R&D Spending Fluctuations: Expected uptick in R&D spending in Q2 followed by a decrease in Q3 and Q4, indicating potential volatility in financial performance.
• Regulatory Risks: The NOPAIN Act, which has expanded coverage for EXPAREL, is set to expire in 2027, raising concerns about future reimbursement landscapes.

5. Notable Q&A Insights

• Elective Procedure Trends: Procedures related to EXPAREL are up in the mid-single digits, with a flat year-over-year moving annual total.
• Competitive Landscape: Discussion around emerging therapies for knee OA, with confidence in PCRX201's differentiation based on durability and cost-effectiveness.
• Partnership Development: Ongoing efforts to expand partnerships, particularly in international markets, are seen as crucial for future revenue growth.

Overall, Pacira BioSciences reported solid growth in its key products and maintained a positive outlook for 2026, while acknowledging challenges related to external factors and regulatory timelines.